Brasofensine
![](/Images/godic/202501/01/Brasofensine.svg2206.png")
![U.S. Patent 5,374,636 Peter Moldt, Jørgen Scheel-Krüger, Leif H. Jensen; Neurosearch A/S (NS-2359)](/Images/godic/202501/01/BTfensine2207.GIF")
Brasofensine (NS-2214, BMS-204756) is a phenyltropane that had been under development for the treatment of Parkinson's and Alzheimer's disease. Phase II trials were conducted in 1996 and brasofensine was shown to be both effective and well tolerated at a dose of 4 mg, however development was stopped after in vivo cis-anti isomerization of the 2α-methyloxime group was reported. In animal models of Parkinson's disease, brasofensine was effective in stimulating LMA and reversing akinesia.